Last updated: March 1, 2026
What are the key facts of the case?
Genentech, Inc., filed patent infringement suit against Samsung Bioepis Co. Ltd., in the U.S. District Court for the District of Delaware, case number 1:20-cv-00859. The case concerns claims that Samsung Bioepis' biosimilar products infringe patents held by Genentech related to the drug Avastin (bevacizumab). The suit was filed on April 16, 2020.
Patent allegations
- the patents at issue primarily protect methods of use and manufacturing processes for bevacizumab.
- the patents listed include U.S. Patent Nos. 8,478,359 and 8,702,214, with expiry dates in the 2030s.
- Samsung Bioepis' products targeted for infringement likely include biosimilar versions of Avastin.
Court proceedings
- The case has seen multiple procedural developments, including motions to dismiss and claim construction disputes.
- Bench trials or jury trials are typical in this context, but no final determination has been publicly recorded as of the latest update.
Settlement and licensing
- Certain biosimilar manufacturers have settled patent disputes with originators, but there is no public record of a settlement between Genentech and Samsung Bioepis as of now.
What is the current legal posture?
- As of the latest available docket entries in early 2023, the case remains active, with pretrial proceedings ongoing.
- Disputes focus on claim scope and validity, with Samsung challenging patent validity through various legal defenses, including non-infringement and patentability arguments.
- Patent validity challenges include arguments based on obviousness and prior art invalidity.
What are the implications for biosimilar market entrants?
- The case exemplifies the patent litigation landscape for biosimilars, emphasizing the importance of patent portfolios and legal strategies.
- Samsung Bioepis' potential biosimilar launches might be delayed by patent disputes.
- Patent litigation often results in either licensing agreements or injunctions, shaping the competitive landscape.
Comparative context: Litigation trends in biosimilars
| Aspect |
Typical Biosimilar Litigation |
Genentech v. Samsung Bioepis Facts |
| Patent scope |
Broad, covering manufacturing, use, and formulation |
Focused on method of use and manufacturing patents for Avastin |
| Duration |
2-5 years |
Ongoing, with proceedings since 2020 |
| Outcomes |
Settlement, licensing, or injunctive relief |
Pending resolution, with no final ruling issued |
| Strategies |
Validity challenges, non-infringement arguments |
Similar, with emphasis on patent validity defenses |
What is the strategic importance for stakeholders?
- For originators like Genentech, protecting patent rights remains central in deter biosimilar competition.
- For biosimilar manufacturers, navigating patent landscapes requires careful patent clearance and readiness to defend validity claims.
- Patent litigation still predominates as a barrier to biosimilar market entry, affecting pricing and access.
Key legal points
- the case hinges on the interpretation of patent claims related to complex biologic manufacturing processes.
- Samsung Bioepis' defense likely relies on prior art references and arguments that patent claims are overly broad or obvious.
- Genentech's litigation strategy involves asserting patent rights to block biosimilar commercialization.
Summary
Genentech’s patent infringement lawsuit against Samsung Bioepis centers on patent rights protecting Avastin manufacturing and use methods. The case underscores the ongoing patent battles in the biosimilar sector, with active litigation expected to influence market access timings. The outcome will clarify patent enforceability in biologic drugs and inform biosimilar development strategies.
Key Takeaways
- The case involves multiple patents with expiry dates in the 2030s, presenting long-term patent protection challenges.
- Litigation may delay biosimilar entry, affecting price competition and drug access.
- Samsung Bioepis challenges patent validity, potentially leading to license agreements or patent invalidation.
- Patent disputes remain a significant entry barrier in the biosimilar landscape.
- The case’s resolution will impact biosimilar patent enforcement and litigation trends nationally and globally.
FAQs
1. What specific patents does Genentech claim Samsung Bioepis infringes?
Genentech claims infringement of U.S. Patent Nos. 8,478,359 and 8,702,214, which cover methods of use and manufacturing of bevacizumab.
2. How long are the patents involved in the dispute valid?
These patents have expiry dates around 2034, providing extended protection for the original biologic.
3. What defenses does Samsung likely use?
Samsung argues patent invalidity based on prior art, obviousness, or non-infringement of the claimed methods.
4. What is the potential impact of this case on biosimilar market entry?
If Samsung prevails, biosimilar launch could proceed without licensing; if Genentech wins, biosimilars may face injunctions or licensing requirements.
5. Are there similar cases in the biosimilar field?
Yes, settlement and litigation between originators and biosimilar developers are common, often involving patent battles over key biologics like Humira and Remicade.
References
[1] U.S. District Court, District of Delaware. (2020). Genentech, Inc. v. Samsung Bioepis Co. Ltd. | Case No. 1:20-cv-00859. Public filings available via PACER.
